secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2023-08-04T23:59:59+00:00
Accession:  0001723128-23-000027
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal Q2 revenue up 7% to $599M, net income $12M; raises 2023 guidance
-----------------------------------------------------------------------

- Q2 net revenue $599M, +7% YoY; GAAP net income $12M vs loss $121M prior year.
- Adjusted net income $57M, adjusted EBITDA $146M (+9% YoY), adjusted diluted EPS $0.19.
- Raising 2023 full year guidance following strong H1 performance.
- Growth driven by Generics (complex portfolio, biosimilars), AvKARE expansion, and Specialty.
- Company addressing U.S. drug shortages as one of largest domestic manufacturers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312823000027/0001723128-23-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312823000027/amrx-20230804.htm
  HTML page:      https://secwatch.observer/filing/0001723128-23-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer